Earnings Results and Extension of Marketing Authorization - Research Reports on Valeant, Allergan, AstraZeneca, Teva and Cigna

NEW YORK, August 5, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Allergan Inc. (NYSE: AGN), AstraZeneca PLC (NYSE: AZN), Teva Pharmaceutical Industries (NYSE: TEVA) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5449-100free.

--
Valeant Pharmaceuticals International, Inc. Research Reports
On July 31, 2014, shares in Valeant Pharmaceuticals International, Inc. (Valeant) declined 6.68% to end the trading session at $117.39, on lower profit forecast. For Q2 2014, Valeant's total revenues were $2.0 billion, up 86.3% YoY, driven by strong growth in almost all of businesses, including a rebound in Emerging Markets in Europe, continued strong results in Asia, and robust performance in the U.S. contact lens business, and the U.S. Bausch + Lomb consumer businesses. The Company reported net income of $125.8 million or $0.37 per diluted share, compared with net income of $10.8 million or $0.03 per diluted share in Q2 2013. Valeant has lowered its full-year 2014 revenue and earnings outlook, with revenue expectations of $8.0 billion - $8.3 billion, less than the $8.3 billion - $8.7 billion it previously expected, while EPS is estimated to total $7.90-$8.10, less than the $8.55-$8.80 as predicted earlier. The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Aug-05-2014/VRX/report.pdf

--
Allergan Inc. Research Reports
On July 25, 2014, Allergan, Inc. (Allergan) announced that the European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema (DME) who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. Allergan expects the final decision from the European Commission within a few months. The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Aug-05-2014/AGN/report.pdf

--
AstraZeneca PLC Research Reports
On July 31, 2014, AstraZeneca PLC (AstraZeneca) reported Q2 2014 financial results and raised its full-year 2014 earnings guidance. Sales for the period rose 3.6% YoY to $6.5 billion, despite generic competition to some drugs, generating core earnings, up 8.3% YoY at $1.30 per share. Industry analysts, on average, had forecast sales of $6.29 billion and earnings of $1.10 a share, according to Thomson Reuters data. AstraZeneca now expects 2014 revenue to be in line with 2013 (constant exchange rate), an increase from its earlier guidance of low-to mid-single digit percentage decline. AstraZeneca also boosted its lung drug franchise further by acquiring rights to revenues from Spanish group Almirall's lung treatments in a deal worth up to $2.1 billion. The full research reports on AstraZeneca are available to download free of charge at:

http://www.analystsreview.com/Aug-05-2014/AZN/report.pdf

--
Teva Pharmaceutical Industries Research Reports
On July 31, 2014, Teva Pharmaceutical Industries (Teva) reported a net income attributable to the Company of $748 million or $0.87 per diluted share for Q2 2014, compared with a loss of $452 million or $0.53 per share in Q2 2013. Excluding special items, adjusted EPS rose to $1.23 in Q2 2014 from $1.20 in Q2 2013. Net revenue rose 2.5% YoY to $5.05 billion, driven largely by generic drug sales. Analysts polled by Thomson Reuters had expected per share profit of $1.21 and revenue of $5.08 billion. Teva also declared a cash dividend of NIS 1.21 per share (approximately 35.3 cents), the record date for which is August 21, 2014, while September 4, 2014 is the payment date. The Company has raised EPS guidance for 2014 to $4.90-5.10 in the exclusive Copaxone scenario, and to $4.50-4.80 in the generic Copaxone scenario. The full research reports on Teva are available to download free of charge at:

http://www.analystsreview.com/Aug-05-2014/TEVA/report.pdf

--
Cigna Corp. Research Reports
On July 31, 2014, Cigna Corp. (Cigna) reported its Q2 2014 financial results. Revenue for the period was up 9.4% YoY to $8.7 billion. Q2 2014 net income rose to $573 million, or $2.12 per share, from $505 million, or $1.76 per share, in Q2 2013. Excluding investment gains, the Company earned $1.96 per share, as compared to $1.76 in Q2 2013. Analysts, on average, had expected $1.84, according to Thomson Reuters. Cigna also raised its 2014 earnings outlook and now expects consolidated adjusted income from operations in the range of $1.94 billion to $2.0 billion, or $7.20 to $7.40 per share. "Our sustained growth in a dynamic marketplace is driven by our commitment to innovation and our differentiated capabilities for the benefit of our customers and clients around the world," said David M. Cordani, President and CEO. "This customer focus and our diversified portfolio enable us to deliver attractive growth over the long-term." The full research reports on Cigna are available to download free of charge at:

http://www.analystsreview.com/Aug-05-2014/CI/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED